Related Experiment Video
Updated: Sep 13, 2025

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
Published on: September 27, 2014
25 Years of Ebola Virus VP35 Research
Grace Uwase1, Daisy W Leung2, Gaya K Amarasinghe1
1Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
None:
Ebola virus (EBOV) is a highly virulent non-segmented, negative-sense RNA virus and a causative agent of severe, often fatal disease in humans. EBOV encodes 7 genes and viral protein 35 (VP35) plays a key role in EBOV pathogenesis. VP35 is an EBOV polymerase cofactor that facilitates host immune evasion, viral RNA synthesis, and nucleocapsid assembly. Over the past 25 years since the first recognition that VP35 can antagonize innate immune responses, considerable progress has been made to define the molecular mechanisms by which VP35 mediates its multiple functions and interactions with host factors. Much of this work is based on our understanding of the VP35 sequence and structure as it relates to function. Here, we will provide a comprehensive review of the VP35 structure and known insights into function. Given its significant role, VP35 has also emerged as a therapeutic target for the development of countermeasures against EBOV.
More Related Videos
08:40Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
Published on: March 1, 2019
06:02Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors
Published on: September 13, 2018